Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms LP 001, LP-001 |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 1 | China | 16 Sep 2022 | |
Anemia | Phase 1 | China | 30 Aug 2022 | |
Breast Cancer | Phase 1 | China | - | |
Carcinoma | Phase 1 | China | - | |
Colorectal Cancer | Phase 1 | China | - | |
Lung Cancer | Phase 1 | China | - | |
Stomach Cancer | Phase 1 | China | - |
Phase 1 | - | LP-001 1.6 μg/kg | vooxllwkds(wqrdexuuou) = nnuschpyal jqjkmoroos (yqkhctkrdi ) | Positive | 01 Apr 2024 |